Skip to main contentSkip to navigation
Sirius Investors
Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc.

INXB
NASDAQHealthcare

Inhibrx Biosciences, Inc. (INXB) Investment Research Dashboard

About Inhibrx Biosciences, Inc. (INXB) stock analysis

Get live INXB stock price $15.86, comprehensive Inhibrx Biosciences, Inc. stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time INXB stock data and investment insights.

15.86
13.94%Today
Market Cap
225.87M
Volume
725.34K
52W High
18.95
52W Low
12.95

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Inhibrx Biosciences, Inc. operates as a clinical-stage biopharmaceutical entity, primarily focused on developing advanced biologic treatments for critical, life-threatening medical conditions. Key assets within its development pipeline include: INBRX...

Company Information

CEO
Mark Paul Lappe
Sector
Healthcare
Industry
Biotechnology
Employees
166

Contact Information

Address
11025 North Torrey Pines Road
Country
US

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Higher growth potential with elevated volatility (Beta: 2.88)

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Inhibrx Biosciences, Inc. shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Inhibrx Biosciences, Inc.
  • Investors should consider how Inhibrx Biosciences, Inc. fits within their overall portfolio allocation

Market Cap

225.87M

0

Beta

2.88

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

80/100 ⭐⭐⭐⭐⭐

Overall
+0.7%
NYSE
+0.6%
NASDAQ
+0.7%
Sector1D1W1MP/EScore
Financial Services+2.2%+5.7%+6.1%19.3
98/100⭐⭐⭐⭐⭐
Communication Services+1.4%+2.9%+4.3%22.2
86/100⭐⭐⭐⭐⭐
Healthcare+0.7%+3.3%+3.5%24.1
80/100⭐⭐⭐⭐⭐
Basic Materials+0.4%+1.1%-0.2%25.2
56/100⭐⭐⭐⭐
Consumer Defensive-0.2%+1.7%+1.2%29.7
56/100⭐⭐⭐⭐
Real Estate-0.5%-0.1%-1.6%29.2
43/100⭐⭐⭐
Energy-2.1%-5.8%-5.1%19.1
39/100⭐⭐
Utilities-1.0%-3.0%-5.9%26.8
28/100⭐⭐
Industrials+0.6%+1.7%-11.2%30.1
26/100⭐⭐
Consumer Cyclical+0.5%-0.4%-6.3%43.0
21/100
Technology+0.6%-2.3%-9.6%40.7
17/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-29.